News & Updates
Filter by Specialty:
ARANOTE: Darolutamide plus ADT delays progression in mHSPC
28 Feb 2025
byStephen Padilla
The use of darolutamide (DARO) in addition to androgen deprivation therapy (ADT) is effective at improving radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) compared with placebo plus ADT, irrespective of disease volume, according to the subanalysis of the phase III ARANOTE trial.
ARANOTE: Darolutamide plus ADT delays progression in mHSPC
28 Feb 2025
Low-dose aspirin halves recurrence risk in select CRC patients
28 Feb 2025
byAudrey Abella
In colorectal cancer (CRC) patients harbouring mutations in the PI3K pathway, adjuvant treatment with aspirin 160 mg daily reduced the recurrence rate by over 50 percent, according to the 3-year results from the ALASCCA trial.
